Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shengxuebao granules (also known as Sheng Xue Bao Ke Li) is a traditional Chinese medicine (TCM) herbal granule developed and manufactured by Hunan Kangshou Pharmaceutical. It is a multi-herb preparation containing processed Polygonum multiflorum, Ligustrum lucidum, mulberry, Eclipta prostrata, Radix Paeoniae Alba, Radix Astragali, and Cibotium rhizome (Dog Ridge). Shengxuebao granules are indicated to nourish the liver and kidney, nourish qi, and produce blood. It is clinically used to treat symptoms of liver and kidney deficiency, such as fatigue, dizziness, tinnitus, palpitations, and insomnia, as well as leukopenia caused by radiotherapy and chemotherapy, and iron-deficiency anemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shengxuebao granules.